1 / 2

In Vitro Diagnostics Market worth $87.93 Billion by 2023

The In Vitro Diagnostics Market is projected to reach USD 87.93 billion by 2023 from USD 68.12 billion in 2018, at a CAGR of 5.2%.<br><br>The IVD market, by application is segmented into infectious diseases, diabetes, oncology, cardiology, drug testing/pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology, and other applications (including genetic disease screening and human leukocyte antigen typing).

Download Presentation

In Vitro Diagnostics Market worth $87.93 Billion by 2023

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. In Vitro Diagnostics Market worth $87.93 Billion by 2023 Factors such as increasing burden of chronic diseases (majorly due to the rising geriatric population), rising prevalence of infectious diseases, rising demand for early disease diagnosis using specialized tests, growing awareness on personalized medicine, increasing adoption of fully-automated instruments and automation in laboratories, and increasing adoption of point-of- care testing are driving the market growth. The In Vitro Diagnostics Market is projected to reach USD 87.93 billion by 2023 from USD 68.12 billion in 2018, at a CAGR of 5.2%. The oncology segment is expected to grow at the highest CAGR in the in vitro diagnostics market The IVD market, by application is segmented into infectious diseases, diabetes, oncology, cardiology, drug testing/pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology, and other applications (including genetic disease screening and human leukocyte antigen typing). The infectious diseases accounted for the largest share of this market, while oncology is expected to grow at the highest CAGR during the forecast period. The increasing number of cancer cases across the globe, growing demand for personalized medicine treatment, the increasing utility of biomarkers, and availability of funding for cancer research are some of the major factors propelling the growth of this application segment. Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703 Point-of-care testing segment will continue to grow at higher rate till 2023. On the basis of end users, the in vitro diagnostics market is segmented into hospitals, laboratories, poit-of-care testing, patient self-testing, academic institutes, and other end users. The hospitals segment held the largest share of this market in 2017, while point-of-care testing segment is expected to register highest growth during the forecast period. Regional Analysis:- The in vitro diagnostics market, by region, has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2017, North America dominates the market; and Asia Pacific is expected to witness the highest CAGR during the forecast period, owing to factors such as government efforts to increase awareness about the early detection of diseases and regular health check-ups; continuously rising healthcare expenditure; increasing

  2. number of hospitals and clinical diagnostic laboratories in India and China; and strengthening research base for diagnostic procedures across India, China, and Japan. Read More: - https://www.marketsandmarkets.com/PressReleases/ivd-in-vitro- diagnostics.asp Top Key players:- The top five players in this market hold a share of ~55–60% in 2017. Roche Diagnostics Limited (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott Laboratories (US), and Thermo Fisher Scientific (US) are the leading players in this market. Major players in this market are continuously focusing on securing higher market shares through product launches, expansions, agreements, partnerships, collaborations, and acquisitions. About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA : 1-888-600-6441 sales@marketsandmarkets.com

More Related